Phase IIA Study in Patients With Schizophrenia

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Schizophrenia

Treatments: Drug: Olanzapine; Drug: Placebo; Drug: AZD2624

Study type: Interventional

Funder types: Industry

Identifiers

NCT00686998

D0970C00004

Details and patient eligibility

About

This study is designed to assess the effects of AZD 2624 in patients with schizophrenia

Enrollment: 106 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Females of non-childbearing potential
• Diagnosis of Schizophrenia

Exclusion criteria

• Clinically relevant disease and /or abnormalities.
• Alcohol or substance abuse not in remission
• Enrollment in another investigational study within 30 days

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

106 participants in 3 patient groups, including a placebo group

AZD2624

Experimental group

Description:

AZD2624 40 mg

Treatment:

Drug: AZD2624

Olanzapine

Other group

Description:

Olanzapine 15 mg

Treatment:

Drug: Olanzapine

Placebo

Placebo Comparator group

Description:

Matching Placebo

Treatment:

Drug: Placebo